Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
TNXP

TNXP - Tonix Pharmaceuticals Holding Corp Stock Price, Fair Value and News

2.13USD-0.08 (-3.62%)Market Closed

Market Summary

TNXP
USD2.13-0.08
Market Closed
-3.62%

TNXP Stock Price

View Fullscreen

TNXP RSI Chart

TNXP Valuation

Market Cap

209.2M

Price/Earnings (Trailing)

-2.12

Price/Sales (Trailing)

26.94

Price/Free Cashflow

-2.3

TNXP Price/Sales (Trailing)

TNXP Profitability

Operating Margin

38.97%

Return on Equity

-91.17%

Return on Assets

-72.85%

Free Cashflow Yield

-43.43%

TNXP Fundamentals

TNXP Revenue

Revenue (TTM)

7.8M

Rev. Growth (Yr)

86.45%

Rev. Growth (Qtr)

-34.32%

TNXP Earnings

Earnings (TTM)

-98.6M

Earnings Growth (Yr)

54.74%

Earnings Growth (Qtr)

45.32%

Breaking Down TNXP Revenue

Last 7 days

-55.8%

Last 30 days

1188.2%

Last 90 days

563.6%

Trailing 12 Months

25.9%

How does TNXP drawdown profile look like?

TNXP Financial Health

Current Ratio

1.47

Debt/Equity

0.06

Debt/Cashflow

-14.07

TNXP Investor Care

Shares Dilution (1Y)

823.99%

Diluted EPS (TTM)

-3.98

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
20231.9M3.9M5.8M7.8M
2011006.3K0
20100000

Tracking the Latest Insider Buys and Sells of Tonix Pharmaceuticals Holding Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 29, 2022
lederman seth
bought
34,200
1.71
20,000
chief executive officer
Mar 25, 2022
lederman seth
bought
24,500
0.245
100,000
chief executive officer
Sep 28, 2021
lederman seth
bought
7,320
0.61
12,000
chief executive officer
Jun 30, 2021
saenger bradley
acquired
10,583
0.58
18,248
chief financial officer
Jun 30, 2021
sullivan gregory m
acquired
21,167
0.58
36,496
chief medical officer
May 25, 2021
goodman daniel wintner
bought
5,600
1.12
5,000
-
Mar 24, 2021
lederman seth
bought
22,087
1.32
16,733
chief executive officer
Jan 07, 2021
sullivan gregory m
acquired
21,074
0.51
41,322
chief medical officer
Dec 30, 2020
lederman seth
bought
23,800
0.68
35,000
chief executive officer
Aug 31, 2020
treco james
bought
4,895
0.89
5,500
-

1–10 of 24

Which funds bought or sold TNXP recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 20, 2024
Virtu Financial LLC
new
-
4,000
4,000
-%
May 16, 2024
JANE STREET GROUP, LLC
new
-
2,553
2,553
-%
May 16, 2024
First Western Trust Bank
unchanged
-
-2,239
1,920
-%
May 15, 2024
Beaird Harris Wealth Management, LLC
sold off
-100
-6.00
-
-%
May 15, 2024
Federation des caisses Desjardins du Quebec
new
-
10.00
10.00
-%
May 15, 2024
Altium Capital Management LP
sold off
-100
-217,630
-
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
reduced
-76.92
-15.00
1.00
-%
May 15, 2024
ARMISTICE CAPITAL, LLC
reduced
-87.03
-1,428,360
90,954
-%
May 15, 2024
MORGAN STANLEY
reduced
-1.49
-1,749
1,459
-%
May 15, 2024
SABBY MANAGEMENT, LLC
added
58.16
-336,894,000
910,649,000
0.52%

1–10 of 49

Are Funds Buying or Selling TNXP?

Are funds buying TNXP calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TNXP
No. of Funds

Unveiling Tonix Pharmaceuticals Holding Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
armistice capital, llc
6.71%
3,770,000
SC 13G
Feb 14, 2024
alyeska investment group, l.p.
9.99%
5,855,597
SC 13G
Feb 14, 2024
tang capital partners lp
0.0%
0
SC 13G/A
Jan 11, 2024
empery asset management, lp
9.99%
2,313,680
SC 13G
Jan 03, 2024
sabby management, llc
9.99%
5,205,348
SC 13G
Feb 14, 2023
tang capital partners lp
7.4%
4,500,419
SC 13G/A
Dec 27, 2022
tang capital partners lp
7.4%
4,280,916
SC 13G
Jul 08, 2022
blackrock inc.
1.1%
341,736
SC 13G/A
Feb 04, 2022
blackrock inc.
6.2%
30,631,558
SC 13G
Feb 16, 2021
cvi investments, inc.
-
111,250
SC 13G/A

Recent SEC filings of Tonix Pharmaceuticals Holding Corp

View All Filings
Date Filed Form Type Document
Jun 11, 2024
424B5
Prospectus Filed
Jun 10, 2024
8-K
Current Report
Jun 06, 2024
8-K
Current Report
Jun 06, 2024
8-K
Current Report
Jun 03, 2024
8-K
Current Report
May 30, 2024
8-K
Current Report
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading

Peers (Alternatives to Tonix Pharmaceuticals Holding Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
56.9B
6.8B
26.49% 20.13%
-9.53
8.3
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.8B
2.0B
3.96% -18.99%
-59.59
9.88
75.20% 68.82%
15.9B
2.5B
3.50% -10.13%
77.51
6.44
13.74% 186.89%
13.4B
3.8B
12.10% -4.22%
17.92
3.54
8.58% 129.81%
MID-CAP
5.2B
524.1M
1.76% -52.84%
-12.43
9.9
394.93% 39.61%
5.1B
107.9M
-5.57% 73.81%
-9.41
48.09
54.84% -28.31%
3.4B
251.0M
-1.97% -5.04%
-11.39
13.45
73.58% -86.73%
3.1B
240.7M
11.59% -30.36%
-6.47
12.77
-1.03% -213.92%
2.5B
813.8M
-1.44% -38.93%
-1.5K
3.05
56.43% 98.83%
2.3B
996.6M
88.40% 115.04%
-5.89
2.36
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-2.38% 30.76%
28.22
4.47
60.38% -34.49%
537.6M
881.7K
17.03% 459.00%
-15.93
481.06
-77.61% 33.36%
251.6M
4.2M
-8.83% 61.83%
-2.01
60.48
-66.30% 48.24%
21.2M
2.1M
32.97% 237.68%
-0.92
7.61
-13.45% 69.54%

Tonix Pharmaceuticals Holding Corp News

Latest updates
Investing.com13 hours ago
GlobeNewswire06 Jun 202403:01 pm

Tonix Pharmaceuticals Holding Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12011Q32011Q22010Q32010Q2
Revenue-34.3%2,4823,7793,9892,6601,3312.001.001.002.00
Cost Of Revenue-1,660-2,374------
Costs and Expenses-23.4%23,83331,10832,13629,00233,902----
Operating Expenses------1,014356--
  S&GA Expenses-19.9%9,31011,6228,7127,0267,391----
  R&D Expenses-24.9%12,86317,11921,05021,97626,511----
Interest Expenses------8*22*--
Income Taxes----------
Net Income45.3%-14,939-27,322-27,975-28,356-33,005----
Net Income Margin15.5%-12.69*-15.02*-20.77*-31.40*-30.05*----
Free Cashflow22.4%-17,683-22,778-25,198-25,212-36,710----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-12.4%13515413916017922624327622424121518918498.0068.0058.0034.0015.0012.0015.0020.00
  Current Assets-37.0%30.0048.0031.0051.0084.0013115119215318919517717388.0062.0058.0033.0014.0012.0014.0019.00
    Cash Equivalents-71.7%7.0025.007.0026.0072.0012014014514017918316616477.0056.0055.0031.0011.0010.0012.0017.00
  Inventory-9.4%12.0014.0013.0014.00-----------------
  Net PPE-1.0%93.0094.0095.0096.0094.0094.0090.0083.0070.0051.0018.0010.009.009.004.000.000.000.000.000.000.00
  Goodwill0%1.001.001.001.00-----------------
Liabilities-44.4%27.0049.0018.0019.0014.0019.0014.0016.0016.0022.0013.009.007.0011.005.005.003.005.002.002.002.00
  Current Liabilities8.4%20.0019.0018.0018.0013.0018.0013.0016.0015.0022.0012.008.006.0010.004.005.003.005.002.002.002.00
  Long Term Debt-6.1%6.007.00-------------------
    LT Debt, Current20.0%3.002.00-------------------
    LT Debt, Non Current-6.1%6.007.00-------------------
Shareholder's Equity2.5%10810612114016520722922820821920218017788.0063.0054.0031.009.0010.0013.0018.00
  Retained Earnings-2.5%-615-600-573-545-516-470-438-409-386-359-330-311-288-267-250-238-224-217-208-200-194
  Additional Paid-In Capital2.5%724706694686683677667638594579532492465355313292256227218213213
Shares Outstanding25.8%74.0059.0018.0011.0010.0012.007.004.003.003.002.002.00---------
Float----17.00---50.00---384---63,914---7,273-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations21.3%-17,575-22,340-23,385-23,367-32,911-22,301-23,535-21,171-31,046-22,445-12,946-19,108-21,058-13,914-15,285-10,041-9,326-6,683-6,645-4,713-8,642
  Share Based Compensation-17.0%1,6922,0382,0792,3642,7942,7162,7652,8132,6202,2962,3022,0891,212871912733360359362431305
Cashflow From Investing74.9%-108-431-821-24,019-3,799-4,671-8,820-14,439-20,217-25,622-7,751-1,429-505-4,534-4,016---5.00-2.00-3.00-7.00
Cashflow From Financing-100.5%-21240,7146,2741,029-11,5007,229-4,62572,17713,06343,76737,96122,049108,71039,85920,06934,42028,7577,9144,51541773.00
  Buy Backs-----13,965----------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

TNXP Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
REVENUES:  
Product revenue, net$ 2,482
COSTS AND EXPENSES:  
Cost of sales1,660
Research and development12,86326,511
General and administrative9,3107,391
Total operating expenses23,83333,902
Operating loss(21,351)(33,902)
Gain on change in fair value of warrant liabilities7,005
Other (expense) income, net(593)897
Net loss available to common stockholders$ (14,939)$ (33,005)
Net loss per common share, basic$ (0.18)$ (3.21)
Net loss per common share, diluted$ (0.18)$ (3.21)
Weighted average common shares outstanding, basic80,879,10810,268,500
Weighted average common shares outstanding, diluted80,879,10810,268,500

TNXP Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 7,049$ 24,948
Inventory, net12,35113,639
Prepaid expenses and other current assets10,6989,181
Total current assets30,09847,768
Property and equipment, net93,05894,028
Intangible assets, net9,5059,743
Goodwill965965
Operating lease right-to-use assets757824
Other non-current assets9601,129
Total assets135,343154,457
Current liabilities:  
Accounts payable6,6493,782
Accrued expenses and other current liabilities10,73312,482
Term loan payable, short term2,8202,350
Lease liability, short term277270
Total current liabilities20,47918,884
   
Term loan payable, long term6,1586,561
Lease liability, long term563632
Total liabilities27,20048,932
Stockholders’ equity:  
Preferred stock, $0.001 par value; 5,000,000 shares authorized, 0 shares designated as of both March 31, 2024, and December 31, 2023; 0 shares issued and outstanding - as of both March 31, 2024 and December 31, 2023
Common stock, $0.001 par value; 1,000,000,000 shares authorized; 73,724,196 and 58,614,593 shares issued and outstanding as of March 31, 2024, and December 31, 2023, respectively and 66,359 shares to be issued as of December 31, 20237459
Additional paid in capital723,906706,356
Accumulated deficit(615,597)(600,658)
Accumulated other comprehensive loss(240)(232)
Total stockholders’ equity108,143105,525
Total liabilities and stockholders’ equity135,343154,457
Series C Warrant [Member]  
   
Warrant liabilities14,595
Series D Warrant [Member]  
   
Warrant liabilities$ 8,260
TNXP
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, develops therapeutics and vaccines to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed to treat autoimmune conditions. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; and TNX-102 SL, a CNS product candidate to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a recombinant protein enzyme to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
 CEO
 WEBSITEtonixpharma.com
 INDUSTRYBiotechnology
 EMPLOYEES117

Tonix Pharmaceuticals Holding Corp Frequently Asked Questions


What is the ticker symbol for Tonix Pharmaceuticals Holding Corp? What does TNXP stand for in stocks?

TNXP is the stock ticker symbol of Tonix Pharmaceuticals Holding Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tonix Pharmaceuticals Holding Corp (TNXP)?

As of Tue Jun 11 2024, market cap of Tonix Pharmaceuticals Holding Corp is 209.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TNXP stock?

You can check TNXP's fair value in chart for subscribers.

What is the fair value of TNXP stock?

You can check TNXP's fair value in chart for subscribers. The fair value of Tonix Pharmaceuticals Holding Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Tonix Pharmaceuticals Holding Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TNXP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Tonix Pharmaceuticals Holding Corp a good stock to buy?

The fair value guage provides a quick view whether TNXP is over valued or under valued. Whether Tonix Pharmaceuticals Holding Corp is cheap or expensive depends on the assumptions which impact Tonix Pharmaceuticals Holding Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TNXP.

What is Tonix Pharmaceuticals Holding Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jun 11 2024, TNXP's PE ratio (Price to Earnings) is -2.12 and Price to Sales (PS) ratio is 26.94. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TNXP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Tonix Pharmaceuticals Holding Corp's stock?

In the past 10 years, Tonix Pharmaceuticals Holding Corp has provided -0.749 (multiply by 100 for percentage) rate of return.